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Background. Bacterial meningitis remains a major disease affecting children in Côte d’Ivoire. Thus, with support from the 
World Health Organization (WHO), Côte d’Ivoire has implemented pediatric bacterial meningitis (PBM) surveillance at 2 sentinel 
hospitals in Abidjan, targeting the main causes of PBM: Streptococcus pneumoniae (pneumococcus), Haemophilus influenzae, and 
Neisseria meningitidis (meningococcus). Herein we describe the epidemiological characteristics of PBM observed in Côte d’Ivoire 
during 2010–2016.
Methods. Cerebrospinal fluid (CSF) was collected from children aged <5  years admitted to the Abobo General Hospital or 
University Hospital Center Yopougon with suspected meningitis. Microbiology and polymerase chain reaction (PCR) techniques 
were used to detect the presence of pathogens in CSF. Where possible, serotyping/grouping was performed to determine the specific 
causative agents.
Results. Overall, 2762 cases of suspected meningitis were reported, with CSF from 39.2% (1083/2762) of patients analyzed at the 
WHO regional reference laboratory in The Gambia. In total, 82 (3.0% [82/2762]) CSF samples were positive for bacterial meningitis. 
Pneumococcus was the main pathogen responsible for PBM, accounting for 69.5% (52/82) of positive cases. Pneumococcal conju-
gate vaccine serotypes 5, 18C, 19F, and 6A/B were identified post–vaccine introduction. Emergence of H. influenzae nontypeable 
meningitis was observed after H. influenzae type b vaccine introduction.
Conclusions. Despite widespread use and high coverage of conjugate vaccines, pneumococcal vaccine serotypes and H. influenzae 
type b remain associated with bacterial meningitis among children aged <5 years in Côte d’Ivoire. This reinforces the need for en-
hanced surveillance for vaccine-preventable diseases to determine the prevalence of bacterial meningitis and vaccine impact across 
the country.
Keywords. Côte d’Ivoire; pediatric; meningitis; pneumococcus; Haemophilus influenzae.
The 26 countries that are within the extended meningitis belt 
across sub-Saharan Africa, including Côte d’Ivoire, experience 
the heaviest burden of bacterial meningitis worldwide. In 2012, 
a meningitis outbreak affecting 10 countries with >11 000 cases 
and 960 deaths occurred [1]. Neisseria meningitidis (meningo-
coccus) was the pathogen responsible for this outbreak, and 
Côte d’Ivoire was 1 country that was affected, with a reported 
399 suspected cases and 49 deaths due to meningococcus, re-
sulting in a case fatality rate of 12.3% [1, 2]. Bacterial menin-
gitis epidemics have been reported in Africa for more than a 
century, with the highest rates of mortality observed in children 
<5 years old [2]. Historically, up to 80% of bacterial meningitis 
cases are caused by Streptococcus pneumoniae (pneumococcus), 
Haemophilus influenzae, and meningococcus [3, 4].
Consequently, in 2008, the World Health Organization 
(WHO) started standardizing invasive bacterial vaccine-
preventable disease (IB-VPD) surveillance, with the aim of 
ensuring that all sentinel hospitals have access to advanced mo-
lecular laboratory diagnostic tests for meningitis [5]. As part 
of this, the WHO established regional reference laboratories 
(RRLs). One such RRL is based at the Medical Research Council 
Unit The Gambia at the London School of Hygiene and Tropical 
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Medicine (MRCG at LSHTM), which supports pediatric bacte-
rial meningitis (PBM) surveillance from 17 sentinel sites across 
West Africa [5]. This includes Côte d’Ivoire, which has a popu-
lation of approximately 26 million, a human immunodeficiency 
virus prevalence of 2.8% in adults aged 15–49 years, and an esti-
mated 10 million children <14 years of age who are most at risk 
of bacterial meningitis infections [6, 7].
In 2009, Côte d’Ivoire introduced the H. influenzae type b (Hib) 
vaccine for children aged 8, 12, and 16 weeks. However, the civil 
war from 2010 to 2011 led to a reduction in routine immunization 
coverage rates from approximately 85% to 62% [8, 9]. Since then, 
the Hib-containing vaccine coverage rate has rapidly improved, 
with WHO/United Nations Children’s Fund estimates at 84% for 
2017 [10]. In 2013, the 13-valent pneumococcal conjugate vaccine 
(PCV13), which targets 13 invasive pneumococcal serotypes, was 
introduced, and coverage was estimated at 99% in 2017 [10, 11]. 
Additionally, in 2014 Côte d’Ivoire conducted vaccination cam-
paigns using the meningococcal conjugate vaccine (MenAfriVac), 
and it is expected that the country will soon apply for funding 
from Gavi, the Vaccine Alliance, to introduce MenAfriVac into 
their routine Expanded Programme on Immunization [12, 13].
With support from the WHO and the MRCG at LSHTM, 
Côte d’Ivoire has implemented surveillance at 2 sentinel hos-
pitals in its capital city, Abidjan, with the aim to provide com-
prehensive surveillance data on children <5  years old with 
suspected meningitis, over a 7-year period. Here, we present a 
summary of this surveillance data for the period 2010–2016.
MATERIALS AND METHODS
Surveillance Design and Target Population
Surveillance of children <5  years old with suspected menin-
gitis, who were admitted to either Abobo General Hospital or 
University Hospital Center Yopougon based in the Abidjan sub-
urbs, was carried out from 2010 through 2016. Children were 
referred by pediatricians at primary and secondary healthcare 
facilities to these sentinel hospitals based on their place of res-
idence. Additionally, some children were admitted directly by 
the hospitals after presenting at the emergency room. Suspected 
meningitis cases were identified using the WHO standard case 
definition by the rapid development of a fever with axillary and 
rectal temperatures >38°C or >38.5°C, respectively, combined 
with at least 1 of the following clinical symptoms: reduced level of 
consciousness, meningismus (stiff neck), photophobia, bulging 
fontanelle (infants), and convulsions or partial seizures [14].
Cerebrospinal Fluid Processing at the Sentinel Site
Confirmed bacterial meningitis cases were defined by the 
identification of bacteria in the cerebrospinal fluid (CSF) [14]. 
A lumbar puncture was performed and CSF samples were col-
lected from suspected cases following a standard operating pro-
cedure developed by the WHO Paediatric Bacterial Meningitis 
Network [5, 15]. Samples were transported to the sentinel site 
laboratory for processing within 1 hour of collection. The CSF 
appearance was recorded, and white blood cell (WBC) counts, 
protein levels, and glucose levels were measured using methods 
previously described [15–17].
An aliquot of CSF was centrifuged and the supernatant 
used in a rapid antigen test with the use of latex agglutina-
tion (Pastorex meningitis kit, Bio-Rad) to detect the presence 
of S.  pneumoniae, H.  influenzae, or N.  meningitidis. Some 
of the sediment was used for Gram staining, while another 
loopful was streaked onto Columbia blood agar and choco-
late agar plates and incubated overnight. On examination, sus-
pected pneumococcal isolates were confirmed via an optochin 
test (5 μg optochin disk, Oxoid), and suspected H.  influenzae 
and meningococcal isolates underwent an analytical profile 
index (API NH, bioMérieux). Where possible, serotyping and 
serogrouping for isolates was performed using various latex 
agglutination techniques, as previously described [18–20]. 
Antibiotic susceptibility tests were performed for commonly 
prescribed antibiotics via disk and Etest diffusion following 
Clinical and Laboratory Standards Institute guidelines [21]. 
Shipment of CSF samples to MRCG at LSHTM was carried out 
in accordance with the International Air Transport Association 
regulations for infectious substances [22].
Molecular Analysis of CSF
Once at MRCG at LSHTM, species-specific real-time polymerase 
chain reaction (PCR) was performed with the following gene 
targets: lytA for S. pneumoniae, hpd for H. influenzae, and sodC 
for N. meningitidis [23, 24]. An RNase P assay was used to con-
firm that samples were of human origin, and cycle threshold (Ct) 
values ≤36 were considered positive results. A sequential triplex 
real-time PCR assay to detect 21 pneumococcal capsular sero-
types was conducted as previously described [25, 26]. Samples 
with Ct values >32 were examined by conventional PCR [27]. 
Targets for N. meningitidis included the sacB, synD, synE, synG, 
xcbB, and synF genes for serogroups A, B, C, W, X, and Y, respec-
tively. For H. influenzae, the following genes were screened for 
serotyping: acsB (type a), bcsB (Hib), ccsD (type c), dscE (type d), 
ecsH (type e), and bexD (type f), following methods described 
elsewhere [28]. Ct values of ≤32 were considered positive.
Statistical Analysis
Surveillance data was recorded by the 2 sentinel hospitals using 
standardized WHO Regional Office for Africa PBM network 
case report forms. Here, details of patient demographics, clinical 
symptoms, and laboratory test results were collected. This infor-
mation was then logged on a WHO Epi Info–based customized 
new vaccines surveillance data module. Data cleaning and anal-
ysis were performed at the sentinel sites and then sent to national 
and regional WHO data managers. All data were analyzed using 
GraphPad Prism 8.1.1 software, and baseline characteristics of 
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the children with suspected meningitis and pathogens detected 
were summarized using descriptive statistics.
Ethical considerations
Ethical approval was not a requirement in Côte d’Ivoire for 
routine meningitis surveillance, including drug susceptibility 
testing of collected isolates, as this is approved within the rou-
tine diagnostic algorithm at the Ministry of Health. However, 
informed consent was sought from caregivers of the surveil-
lance participants. Additionally, the surveillance received over-
arching ethical approval (SCC1188) by the joint MRCG at 
LSHTM/The Gambia government ethics board that allowed the 
analysis of collected West African isolates.
RESULTS
Clinical and Demographic Characterization of Enrolled Cases
Throughout the surveillance period, 2762 children <5 years old 
with suspected bacterial meningitis were recruited. Of these, 
2743 (99.3%) patients were residents of the Abidjan district, an 
additional 13 (0.5%) were from the surrounding Lagunes dis-
trict, and 6 (0.2%) were residents from elsewhere within Côte 
d’Ivoire. A  lumbar puncture was performed for all patients 
recruited, and CSF samples were collected. In total, 1160 of 
2762 (41.9%) CSF samples were sent to the RRL at MRCG at 
LSHTM for analysis (Figure 1), where 1083 of the 1160 (93.4%) 
CSF samples were processed to determine if S.  pneumoniae, 
H. influenzae, or N. meningitidis were present (Figure 1).
Details of the clinical and demographic characteristics of 
the children recruited at either Abobo General Hospital or 
University Hospital Center Yopougon are summarized in 
Table  1. More than half of the children recruited were male 
(1561/2762 [56.5%]), and the median age of patients was 28 
(interquartile range, 8–36) months. The greatest number of sus-
pected cases were seen in the eldest children, aged 24–59 months 
(1271/2762 [46.0%]). Interestingly, 175 of the 2762 (7.1%) pa-
tients reported using antibiotics prior to hospital admission and 
CSF collection. Of the 773 (773/2762 [28%]) patients for whom 
the outcome was recorded, there was a case fatality rate of 6.2%, 
accounting for 48 in-hospital deaths.
The number of suspected bacterial meningitis cases in chil-
dren aged <5 years varied annually, ranging from 74 cases in 
2011 to 726 cases in 2014. The average number of cases annually 
was 394.6. During the surveillance period, a total of 82 (82/2762 
[3.0%]) cases of bacterial meningitis were confirmed from CSF 
samples collected at the sentinel sites. Of these, 57 (69.5%) were 
caused by S.  pneumoniae, 13 (15.8%) by H.  influenzae, and 
an additional 12 (14.6%) by N.  meningitidis. In addition, the 
highest number of meningitis cases caused by these 3 patho-
gens was seen in 2014, with 32 cases, accounting for 39% of the 
total 82 meningitis cases (Figure 2).
Microbial Identity
The most prevalent pathogen causing PBM during the surveil-
lance period was pneumococcus, accounting for 25 of the 35 
(71.4%) meningitis cases seen in children aged 0–11 months, 12 
of the 17 (70.6%) cases seen in children 12–23 months, and 20 of 
the 30 (66.7%) cases seen in children aged 24–59 months. A total 
of 13 cases of bacterial meningitis were caused by H. influenzae, 
and the majority of these were seen in children from the youngest 
age group. Additionally, a further 12 cases of bacterial menin-
gitis were caused by N. meningitidis, with the majority of these 
cases occurring in children in the eldest age group.
An interesting observation was that among the 82 patients 
who had bacterial meningitis, a total of 34 (41.5%) cases 
Figure 1. A breakdown of the suspected pediatric bacterial meningitis cases during surveillance in Côte d’Ivoire, 2010–2016. A total of 2762 cerebrospinal fluid (CSF) sam-
ples were collected from patients with suspected pediatric bacterial meningitis admitted to 2 sentinel hospitals within Abidjan. Diagnostic tests were performed for most 
CSF samples at the sentinel hospitals, and 1160 CSF samples were sent to the World Health Organization regional reference laboratory (Medical Research Council Unit The 
Gambia at the London School of Hygiene and Tropical Medicine) for confirmatory species-specific polymerase chain reaction. Abbreviations: CSF, cerebrospinal fluid; IBD, 
invasive bacterial disease; PCR, polymerase chain reaction; RRL, regional reference laboratory.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/69/Supplem
ent_2/S114/5561325 by London School of H
ygiene & Tropical M
edicine user on 03 February 2020
Pediatric Bacterial Meningitis in Côte d’Ivoire • cid 2019:69 (Suppl 2) • S117
provided CSF samples that were clear in appearance. Moreover, 
of these 34, 22 (64.7%) were identified as positive for pneumo-
coccus. Additionally, a total of 43 of the 82 (52.4%) cases with 
bacterial meningitis had CSF that appeared turbid or cloudy. 
Again, of these the majority (33 [76.7%]) were caused by pneu-
mococcal infections. Furthermore, nearly half the total of PBM 
cases (39/82 [47.5%]) had WBC counts of <10 cells/μL, and 37 
cases had WBC counts of >100 cells/μL (Table 1).
Serotype Distribution
Of the 57 cases of meningitis caused by S. pneumoniae, we identi-
fied the specific serotype of 16 isolates of the bacterium, collected 
from 16 children. We found that 9 of these cases were caused 
by pneumococcal serotypes that are targeted within the PCV13 
vaccine including serotypes 5, 18C, 19F, and 6A/6B/6C/6D. 
On examination with PCR assays, 2 isolates had Ct values >32; 
thus, the DNA concentration was too low to accurately serotype. 
A  further 2 samples were nontypeable by real-time PCR and 
were negative for all 21 serotypes targeted. The remaining 3 
pneumococcal isolates were serotypes that were non-PCV13, in-
cluding 18, 12F/12A/12B/44/46, and 33F (Figure 2).
Of the 13 H.  influenzae cases admitted to the sentinel sites 
during the surveillance period, we performed serotype anal-
ysis on 6 isolates. One-third were positively identified as Hib, 
another third was determined as H.  influenzae type a, and 
the final third were either H. influenzae type f or nontypeable 
by PCR methods (Figure 2). Furthermore, of the 12 cases of 
N. meningitidis observed during 2010–2016, we serogrouped 2 
of these, and both were nongroupable by the methods used and 
were negative for serogroups A, B, C, W, X, and Y.
Interestingly, of the 82 patients with confirmed PBM, 23 
(28%) had received at least 1 dose of the Hib vaccine and 12 
(14.6%) reported receiving all 3 doses (full course). Two cases of 
H. influenzae were detected among patients who had received 
Table 1. Summary of Clinical and Demographic Characteristics of the Study Population
Characteristic 
Total
Streptococcus 
pneumoniae
Haemophilus 
influenzae
Neisseria 
meningitidis
No. (%) No. (%) No. (%) No. (%)
Age group, mo
 0–11 890 (32.2) 25 (71.4) 8 (22.9) 2 (5.7)
 12–23 597 (21.6) 12 (70.6) 2 (11.8) 3 (17.6)
 24–59 1271 (46.0) 20 (66.7) 3 (10.0) 7 (23.3)
 Unknown 4 (0.1) 0 (0) 0 (0) 0 (0)
Sex
 Male 1561 (56.5) 37 (63.8) 10 (17.2) 11 (19.0)
 Female 1199 (43.4) 20 (83.3) 3 (12.5) 1 (4.2)
 Unknown 2 (0.1) 0 (0) 0 (0) 0 (0)
Antibiotic before admission
 Yes 175 (6.3) 2 (33.3) 4 (66.7) 0 (0.0)
 No 1134 (41.0) 16 (76.2) 3 (14.3) 2 (9.5)
 Unknown 1453 (41.3) 39 (70.9) 6 (10.9) 10 (18.2)
CSF appearance
 Clear 2268 (82.1) 22 (64.7) 6 (17.6) 6 (17.6)
 Turbid/cloudy 203 (7.3) 33 (76.7) 6 (14.0) 4 (9.3)
 Xanthrochromic 87 (3.1) 1 (100.0) 0 (0.0) 0 (0.0)
 Blood-stained 197 (7.1) 1 (25.0) 1 (25.0) 2 (50.0)
 Unknown/other 7 (0.3) 0 (0) 0 (0) 0 (0)
WBC count, cells/μL
 ≤10 2602 (94.2) 21 (0.8) 8 (0.3) 10 (0.4)
 >10 to 100 25 (0.9) 5 (20.0) 1 (4.0) 0 (0.0)
 >100 75 (2.7) 31 (42.5) 4 (5.5) 2 (2.7)
 Unknown 60 (2.2) 0 (0) 0 (0) 0 (0)
Outcome
 Discharged alive 214 (7.7) 1 (100.0) 0 (0.0) 0 (0.0)
 Died 48 (1.7) 2 (100.0) 0 (0.0) 0 (0.0)
 Transferred 3 (0.1) 0 (0) 0 (0) 0 (0)
 Left against medical advice 28 (1.0) 7 (58.3) 5 (38.5) 0 (0.0)
 Pending discharge 480 (17.4) 0 (0.0) 0 (0.0) 1 (8.3)
 Unknown 1989 (72.0) 47 (71.2) 7 (10.6) 11 (16.7)
Case typea: suspected 2762 (100.0) 57 (2.1) 13 (0.5) 12 (0.4)
Abbreviations: CSF, cerebrospinal fluid; WBC, white blood cell.
aSuspected cases include cases that were defined as probable as per World Health Organization case definition guidelines [14].
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vaccines; however, serotype analysis had not been successfully 
performed for these isolates. The Hib vaccination status of 46 of 
the 82 (56.0%) patients with PBM was not recorded.
DISCUSSION
We report findings from the first longitudinal surveillance of 
PBM cases within Abidjan, Côte d’Ivoire. There have been a 
number of reports of bacterial meningitis within the men-
ingitis belt previously, but none have focused specifically on 
Côte d’Ivoire and Abidjan alone [8, 29, 30]. The most common 
pathogen found to be associated with PBM was S. pneumoniae, 
responsible for 2.1% of the confirmed meningitis cases we ana-
lyzed. This finding is in line with previous reports in both The 
Gambia and China, which found high levels of pneumococcus 
associated with meningitis [31, 32].
Of the pneumococcal cases that we were able to serotype, 
we found isolates from 4 PCV13 serotypes (5, 18C, 19F, and 
6A/6B/6C/6D) in a total of 9 cases from 2014 through 2016. 
It is well documented that widespread use of pneumococcal 
conjugate vaccines (PCVs) leads to a marked reduction in the 
number of vaccine serotypes carried within the vaccinated and 
unvaccinated populations [33–35]. Côte d’Ivoire introduced the 
PCV13 in 2013, with vaccine coverage rates estimated at 99% 
nationally by 2015 [10]. However, throughout this surveillance 
period, the PVC13 vaccination status of patients with suspected 
meningitis was not recorded. In addition, we found 5 cases of 
non-PCV13 serotypes causing PBM, 4 of which occurred after 
the introduction of PCV13. A  recent United Kingdom–based 
study found that there has been serotype replacement over 5 
winters in pneumococcal carriage of children, whereby vaccine 
serotypes have been replaced by nonvaccine serotypes [36]. The 
increased emergence of non-PCV13 serotypes in a post-PCV13 
era may be due to changes within the bacterial selection pres-
sure caused by the vaccine, leading to the emergence of greater 
number of nonvaccine serotypes [37]. Moreover, a recent study 
by Kwambana-Adams and colleagues found that rapid replace-
ment of PCV serotypes with non-PCV serotypes may diminish 
the impact of the vaccine [38].
We observed an increased number of cases caused by non-
PCV13 serotypes in the post-PCV13 era (after 2013). However, 
as only 24.5% (14/57) of the pneumococcal meningitis cases 
were successfully serotyped, it is difficult to conclude that sero-
type replacement is occurring in Côte d’Ivoire. In addition, it is 
difficult to make this conclusion using this sentinel surveillance 
data alone, especially without details of the PCV13 vaccination 
status of patients. Thus, our data highlight that further work 
within the country is required to ensure high vaccine coverage 
that may lead to herd immunity against vaccine serotypes in 
older children. In addition, further monitoring, reporting, and 
follow-up of the prevalence of both vaccine and nonvaccine 
serotypes post–PCV13 introduction is required in Côte d’Ivoire 
to gain a full picture of the changing etiology of pediatric pneu-
mococcal meningitis.
Of the H. influenzae isolates we serotyped, 2 were positively 
identified as Hib and both occurred during 2016, over 7 years 
after the introduction of the Hib vaccine in Côte d’Ivoire, 
with vaccine coverage rates estimated at 82% nationally 
(Supplementary Table 1) [10]. The remaining 4 isolates we sero-
typed were all non-Hib species (Figure 2). These results high-
light that Hib is still responsible for some cases of PBM within 
children aged <5  years in Côte d’Ivoire despite the introduc-
tion of a conjugate vaccine. Only 2 of the children who were 
positive with H. influenzae infections had received a full course 
of the Hib vaccine, again suggesting that more work is needed 
within the country to ensure high levels of vaccine coverage and 
recording of vaccination status. Moreover, since the introduc-
tion of the Hib vaccine in South Africa, Kenya, and other East 
African regions, surveillance studies have reported meningitis 
cases caused by non-Hib serotypes, which could be due to a 
gradual reduction in the Hib population immunity as a result of 
the vaccine, leading to serotype replacement [35, 39–41]. Due to 
difficulties obtaining correct antisera and primers throughout 
the study, we were unable to serotype all of the H.  influenzae 
samples received at the RRL (MRCG at LSHTM); thus, it is 
difficult to conclude that serotype replacement is occurring. 
However, the findings do show that among a total of 2762 sus-
pected cases of meningitis, only 13 were caused by H. influenzae 
species, accounting for 0.47%, which is encouraging.
Figure 2. The distribution of confirmed pediatric bacterial meningitis cases within 
2 sentinel hospitals in Côte d’Ivoire, 2010–2016. The number of cerebrospinal fluid 
samples that were positive for Streptococcus pneumoniae, Neisseria meningitidis, 
or Haemophilus influenzae during each year of surveillance in Côte d’Ivoire are 
shown. Light gray shading indicates meningitis cases that were caused by bacterial 
serotype/groups targeted by the meningococcal conjugate vaccines (MenAfriVac, 
the 13-valent pneumococcal conjugate vaccine [PCV13], and the H. influenzae type 
b [Hib] vaccine). Dark gray shading highlights cases of H. influenzae meningitis iden-
tified as non–type b, and white shading indicates cases of pneumococcal menin-
gitis caused by serotypes not targeted by PCV13.
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Interestingly, N.  meningitidis was the least abundant path-
ogen seen in PBM, causing only 12 cases of PBM over the sur-
veillance period. It is worth noting that 100% of these cases 
caused occurred in 2014, the same year that the MenAfriVac 
was introduced in Côte d’Ivoire, but, the MenAfriVac status of 
these patients was not recorded. However, since the vaccination 
campaign, there have been no cases of meningococcal menin-
gitis reported in sentinel hospitals within Abidjan, providing 
support for the success of the vaccine at preventing meningo-
coccal disease [42].
Microbiological culture of CSF samples is the current gold 
standard method used to detect the presence of pathogens 
causing meningitis. However, previous studies have shown that 
this has limited sensitivity, especially in patients who have re-
ceived antibiotic treatment prior to CSF collection [20, 43, 44]. 
Data collected from the Global IB-VPD network have shown 
that the bacterial recovery rate from meningitis suspected cases 
by microbiology methods has been low [4, 45]. We found that at 
least 6.3% (175/2762) of suspected cases reported antibiotic use 
prior to admission, and for 52.6% (1453/2762) of the suspected 
cases, antibiotic use prior to admission was unknown. The 2 
sentinel hospitals in Abidjan are large teaching hospitals, which 
receive referrals from primary and secondary healthcare facil-
ities from the Abidjan district and surrounding Lagunes district 
whereby antibiotics may have been prescribed. Hence, antibi-
otic use prior to lumbar puncture may have been underreported 
and contributed to poor bacteriological recovery of pathogens 
in CSF samples.
There are limitations to this study. After diagnostic tests at the 
sentinel hospitals, only 41.9% (1160/2762) of CSF samples had 
sufficient quantity remaining to send to the RRL. Species-specific 
PCR assays could only be completed for 39.2% (1083/2762) of 
the total samples received due to insufficient volumes to allow 
for repeat analysis. In addition, a significant challenge encoun-
tered during this study was the absence of a patient identifi-
cation number on some CSF samples, meaning that PCR data 
generated at MRCG at LSHTM could not be linked to clinical 
data at the sentinel site. This was a particular problem during the 
earlier years of the study and meant that some PCR data gener-
ated could not be added to the analysis presented here.
A further limitation of this study was that valuable informa-
tion was not recorded for many patients. For instance, sequelae 
at discharge was not recorded for 92.6% (2557/2762) of patients 
with suspected meningitis and also not recorded for 81 of the 
82 (98.7%) patients with confirmed PBM. The outcome at dis-
charge was not recorded for 72.0% (1989/2762) of patients with 
suspected meningitis and 78% (64/82) of those with confirmed 
PBM. For future studies, it would be useful to obtain informa-
tion regarding long-term sequelae and outcome at discharge, to 
determine accurate rates of morbidity and mortality associated 
with meningitis in the surveillance population, and to determine 
the level at which vaccination can help prevent this.
CONCLUSIONS
Our surveillance revealed that pneumococcus was the main 
pathogen causing PBM before and after the introduction of 
PCV13 in Côte d’Ivoire. Conjugate vaccine serotypes were still 
detected post–vaccine introduction for both S. pneumoniae and 
H. influenzae. The high number of patients that reported antibi-
otic use before CSF collection may have contributed to the low 
culture recovery rate. We recommend enhanced surveillance 
within Côte d’Ivoire using highly sensitive methods such as 
PCR, to gain a full picture of the prevalence of IB-VPD and the 
serotypes circulating. Additionally, we recommend thorough re-
porting of vaccination status and potential morbidity associated 
with meningitis, to understand the effectiveness of the vaccines 
at reducing bacterial meningitis within children <5 years of age.
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